Bicara Therapeutics (BCAX) Other Operating Expenses (2023 - 2025)

Bicara Therapeutics' Other Operating Expenses history runs 4 years deep, the most recent figure standing at $47.4 million for Q1 2026.

• In Q1 2026, Other Operating Expenses rose 70.76% year-over-year to $47.4 million; the TTM figure through Mar 2026 stood at $172.5 million (up 107.46% YoY), while the FY2025 annual figure was $125.1 million, up 125.79% from the prior year.
• Other Operating Expenses for Q1 2026 stood at $47.4 million, down from $125.1 million in the prior quarter.
• The five-year high for Other Operating Expenses was $125.1 million in Q4 2025, with the low at -$36000.0 in Q3 2024.
• The 4-year median for Other Operating Expenses is $41000.0 (2024), against an average of $23.2 million.
• Peak annual rise in Other Operating Expenses reached 89201.61% in 2024, while the deepest fall reached 192.31% in 2024.
• Bicara Therapeutics' Other Operating Expenses stood at $62000.0 in 2023, then surged by 89201.61% to $55.4 million in 2024, then jumped by 125.93% to $125.1 million in 2025, then slumped by 62.11% to $47.4 million in 2026.
• Business Quant data shows BCAX's Other Operating Expenses at $47.4 million in Q1 2026, $125.1 million in Q4 2025, and -$25000.0 in Q3 2025.